Showing results (1-10 of 328) with videos related to
Sort By:
Pageof 33
La Revue Du Praticien|January 12, 2016
[A YOUNG MAN WHOSE LDL-CHOLESTEROL IS GREATER THAN 1.9 G/L]Bertrand CariouDiabetes, Obesity & Metabolism|January 11, 2022
The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatmentBertrand CariouClinics and Research in Hepatology and Gastroenterology|April 29, 2019
Noninvasive diagnosis of liver fibrosis in NAFLD: Tips tricksFloraine Zuberbuhler, Jerome BoursierJHEP Reports : Innovation in Hepatology|March 4, 2021
Case-finding strategies in non-alcoholic fatty liver diseaseJerome Boursier, Emmanuel A TsochatzisClinics in Liver Disease|April 12, 2016
Nonalcoholic Fatty Liver Disease and the Gut MicrobiomeJerome Boursier, Anna Mae DiehlDiabetes, Obesity & Metabolism|April 20, 2019
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemiaWieneke Dijk, Bertrand CariouExpert Opinion on Investigational Drugs|August 29, 2014
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetesBertrand Cariou, Bart StaelsLa Revue Du Praticien|December 6, 2011
[Management of hypercholesterolemia: what target for LDL cholesterol?]Bertrand Cariou, Michel KrempfDiabetes Research and Clinical Practice|October 1, 2015
mTOR inhibitors and diabetesBruno Vergès, Bertrand CariouTrends in Pharmacological Sciences|April 7, 2007
FXR: a promising target for the metabolic syndrome?Bertrand Cariou, Bart StaelsPageof 33